Binding of LAG-3 to Stable Peptide-MHC Class II Limits T Cell Function and Suppresses Autoimmunity and Anti-Cancer Immunity

Researchers investigated the relative contribution of potential ligands, stable peptide-MHC class II complexes and fibrinogen-like protein 1, to lymphocyte activation gene-3 (LAG-3) activity in vitro and in vivo.